ALiA BioTech is a group of companies that deliver accurate diagnostic information through our Point-Of-Care Testing (POCT) platform and BioChip, for faster clinical decisions and better outcomes for professional and front-line workers.
Our vision remains unchanged, and we have been working hard to become a key/recognized player in Asia with design, knowhow, and manufacturing capability, all vertically integrated.
"Driven by the Covid-19 pandemic, the market for point-of-care testing (POCT) is seen to double in size compared to pre-pandemic levels. In this burgeoning field, multiplexing is the key technology differentiator. Increasing the number of simultaneous assays helps to identify the right biomarker, and thus reduces the cost and time it takes to quell any potential outbreak. We took on this challenge 10 years ago and is now ready to deploy a next-generation rapid diagnostic platform that can conduct multiplex testing in a single biochip within 15 minutes."
